Search results
‘Unusual’ cancers emerged after the pandemic. Doctors ask if covid is to blame.
Washington Post· 16 hours agoKashyap Patel looked forward to his team’s Friday lunches. It was 2021, a year into the coronavirus...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Finance· 8 hours agoThis study has already achieved its primary endpoint – NASH patients who received VK2809 achieved a...
Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2
FierceBiotech· 2 days agoVir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase...
Tattoos may increase blood cancer risk by 21%
MedicalNewsToday via AOL· 6 days agoResearch from Sweden has found a link between getting a tattoo of any size and an overall 21% higher risk of developing lymphoma, a type of blood cancer.
Seattle virologists find promising new results for potential herpes cure: HealthLink
KING5 Seattle· 6 days agoIt is a virus that's been ailing humans for millions of years, but to this day, there has been no...
More rare cancers being diagnosed after the pandemic
Becker’s Hospital Review· 18 hours agoIt's possible that COVID-19 could be another infection that promotes cancer, but conclusive answers are not yet available. "We are completely under-investigating this virus
Cost and Vosevi: How to find savings, lower costs, and more
Medical News Today· 3 days agoThe cost of the drug with and without insurance can depend on several factors, such as whether...
We must remember the heroes of the AIDS epidemic, not just the trauma
LA Times via Yahoo News· 15 hours ago"By 1994...physician who diagnosed Campbell years before, was able to get Jones into the medical...
Get regular blood tests and screening if you have multiple sex partners
Rolling Out· 5 days agoIf you have regular sex partners, getting regular STD testing is an essential part of maintaining...
Arbutus Biopharma (NASDAQ:ABUS) Rating Reiterated by Chardan Capital
ETF DAILY NEWS· 21 hours agoChardan Capital reissued their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a research note released on Wednesday, Benzinga reports. The firm currently ...
